Dr. Joseph Fakhoury discusses what patients can expect during treatment for alopecia areata, offering guidance on response timelines. He explains that responses to Janus kinase (JAK) inhibitor therapy can vary, with some patients experiencing early improvement, while others respond more gradually or later in treatment, emphasizing the importance of allowing adequate time before assessing a treatment’s effectiveness. Dr. Fakhoury also reviews considerations for switching between different JAK inhibitors when an initial treatment is unsuccessful, outlines routine safety monitoring throughout treatment, and discusses strategies for navigating medication access by working closely with their healthcare professionals.
